Scholarlink

Background <p>The management of complex coronary artery disease (CAD) predominantly relies on percutaneous coronary intervention (PCI), yet in-stent restenosis (ISR) remains a critical long-term complication. Emerging evidence implicates immune dysregulation in ISR pathogenesis. </p> Case presentation <p>We present a 74-year-old female with multivessel CAD, recurrent ISR, and comorbidities including hypertension, type 2 diabetes, and hyperlipidemia. Laboratory studies revealed hypogammaglobulinemia M (IgM: 0.306 g/L), an elevated CD4/CD8 ratio (3.24), and elevated hypogammaglobulinemia G3 (IgG3: 0.963 g/L). Intravascular imaging and PET/CT demonstrated neoatherosclerosis with peristrut inflammation. Despite multiple PCIs and guideline-directed medical therapy (GDMT), she experienced recurrent angina. Following adjunctive anti-inflammatory therapy with prednisone and immunomodulation with mycophenolate mofetil, she achieved symptomatic and angiographic stabilization.</p> Conclusion <p>This case suggests a potential association between immune dysregulation and recurrent ISR. Anti-inflammatory and immunomodulatory therapy may represent a novel adjunctive strategy in selected refractory cases, though causality remains speculative and requires further validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune dysregulation complicated by recurrent in-stent restenosis in patients with multivessel coronary artery disease: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月6日

查看全文
  • Jianbang Jiang,
  • Zhiwei Huang,
  • Chongjian Li,
  • Hongliang Zhang,
  • Zhenyan Zhao,
  • Fang Yang,
  • Yusheng Gai,
  • Fei Li,
  • Cancan Gong,
  • Yongjian Wu

摘要

Background

The management of complex coronary artery disease (CAD) predominantly relies on percutaneous coronary intervention (PCI), yet in-stent restenosis (ISR) remains a critical long-term complication. Emerging evidence implicates immune dysregulation in ISR pathogenesis.

Case presentation

We present a 74-year-old female with multivessel CAD, recurrent ISR, and comorbidities including hypertension, type 2 diabetes, and hyperlipidemia. Laboratory studies revealed hypogammaglobulinemia M (IgM: 0.306 g/L), an elevated CD4/CD8 ratio (3.24), and elevated hypogammaglobulinemia G3 (IgG3: 0.963 g/L). Intravascular imaging and PET/CT demonstrated neoatherosclerosis with peristrut inflammation. Despite multiple PCIs and guideline-directed medical therapy (GDMT), she experienced recurrent angina. Following adjunctive anti-inflammatory therapy with prednisone and immunomodulation with mycophenolate mofetil, she achieved symptomatic and angiographic stabilization.

Conclusion

This case suggests a potential association between immune dysregulation and recurrent ISR. Anti-inflammatory and immunomodulatory therapy may represent a novel adjunctive strategy in selected refractory cases, though causality remains speculative and requires further validation.